EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)

Francesca Maria Quaglia, Maria Elena Carazzolo, Antonino Aparo, Alice Parisi, Luisa Lorenzi, Barbara Famengo, Maurilio Ponzoni, Emma Albertini, Riccardo Moia, Francesco Piazza, Alessandro Re, Maria Chiara Tisi und 18 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-11

DOI: 10.1016/j.clml.2026.10.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Francesca Maria Quaglia und 29 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is an incurable disease characterized by marked biological heterogeneity, with early progression of disease (POD, ≤24 months) identifying patients with particularly poor survival. Although morphology, MIPI, and Ki-67 provide established prognostic information, the contribution of molecular heterogeneity to POD remains incompletely defined. The MANTLE-FIRST BIO study enrolled patients with MCL who experienced first relapse or were refractory after frontline chemo-immunotherapy across 16 centers. Nodal/extranodal samples collected at diagnosis underwent centralized histopathological review and targeted next-generation sequencing using a custom 37-gene panel. The primary endpoint was the association between molecular, histopathological and clinical features and time to progression of disease (POD). Eighty-one patients (median age 67 years) were included. Compared with unselected MCL series, this cohort showed a higher frequency of mutations, with ATM (43%), NOTCH1 (32%), SMARCA4 (31%), TP53 (28%) and KMT2D (27%) most frequently altered. TP53 (HR=2.03, p=0.005), NFKBIE (HR=2.72, p=0.022), and STAT3 (HR=2.51, p=0.034) mutations, and CDKN2A deletion (HR=2.26, p=0.007) were associated with shorter time to POD. Three molecular clusters with distinct outcomes were identified. In multivariable analysis, age ≥65 years (HR=4.08, p

Zitieren

APA

Quaglia, F. M., Carazzolo, M. E., Aparo, A., Parisi, A., Lorenzi, L., Famengo, B., Ponzoni, M., Albertini, E., Moia, R., Piazza, F., Re, A., Tisi, M. C., Nassi, L., Bulian, P., Castellino, A., Zilioli, V. R., Stefani, P. M., Fabbri, A., Lucchini, E., …, & Visco, C. (2026). Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.020

Vancouver

Quaglia FM, Carazzolo ME, Aparo A, Parisi A, Lorenzi L, Famengo B, et al. Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL). Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.020

BibTeX
@article{Quaglia2026,
  author = {Quaglia, Francesca Maria and Carazzolo, Maria Elena and Aparo, Antonino and Parisi, Alice and Lorenzi, Luisa and Famengo, Barbara and Ponzoni, Maurilio and Albertini, Emma and Moia, Riccardo and Piazza, Francesco and Re, Alessandro and Tisi, Maria Chiara and Nassi, Luca and Bulian, Piero and Castellino, Alessia and Zilioli, Vittorio Ruggero and Stefani, Piero Maria and Fabbri, Alberto and Lucchini, Elisa and Arcari, Annalisa and Ferrari, Angela and Pironti, Mariapia and Olivieri, Jacopo and Dattoli, Samantha Deianira and Gambino, Simona and Galasso, Marilisa and Salaorni, Vittoria and Krampera, Mauro and Scupoli, Maria Teresa and Visco, Carlo},
  title = {Biological signature to predict early relapse in Mantle Cell Lymphoma patients. Results from the MANTLE-FIRST BIO study on behalf of Fondazione Italiana Linfomi (FIL)},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.020}
}
Kostenlos starten →